Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

Novavax, Moderna, BioNTech Surge To 3-Month High As Omicron Boosters Loom

Vaccine stocks Novavax, Moderna and BioNTech surged to a recent high Friday on growing enthusiasm for an omicron booster campaign in the fall.

Investors Business Daily

Thinking of mixing and matching COVID-19 vaccine booster shots? There doesn't seem to be much point

Most people will have the Moderna or the Pfizer vaccine for their fourth dose. But the Doherty Institute's head of vaccine and immunisation research says there's practically no difference between them.

ABC News

Novavax Gets Expanded Authorization From European Commission For COVID-19 Vaccine

The European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Novavax’s (NASDAQ: NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) for adolescents aged between 12 and 17 years.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The FDA Just Handed BioNTech And Moderna A Gift — But Only One Jumped

The FDA requested vaccine makers update their Covid shots to include an omicron-fighting element on Thursday, and BNTX stock surged.

Investors Business Daily

COVID vaccination reboot coming this fall to add tweaks for new coronavirus variants

The FDA will have to decide the exact recipe. But expect a combination shot that adds protection against omicron or some of its newer relatives to the original vaccine.

Chicago Sun-Times

Taiwan to receive first doses of Novavax COVID vaccine this week

Taiwan will take delivery of its first doses of the Novavax Inc COVID-19 vaccine this week, received under the COVAX sharing scheme, the government said on Wednesday.

Reuters

Should you get a COVID-19 booster shot now or wait until fall? Two immunologists help weigh the options

While COVID-19 vaccines continue to be highly effective at preventing hospitalization and death, it has become clear that the protection offered by the current vaccines wanes over time. This necessitates the use of booster shots that are safe and effective in enhancing the immune response against the virus and extending…

The Conversation

Read news from The Economist, FT, and more,
with one subscription

The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Why Novavax Stock Is Up 11% Today

Novavax Inc (NASDAQ: NVAX) shares are trading higher Thursday after the company announced that its COVID-19 vaccine was recommended for an expanded conditional marketing authorization in the European Union for adolescents aged 12 through 17.

Benzinga

COVID-19 vaccine scheme for world's poorest pushes for delivery slowdown

Leaders of the global scheme aiming to get COVID-19 vaccines to the world's poorest are pushing manufacturers including Pfizer and Moderna to cut or slow deliveries of about half a billion shots so doses are not wasted.

Reuters

IBD/TIPP Poll: There's Bad News For Novavax's Covid Vaccine

Novavax could struggle to find a U.S. market for its Covid shot, according to the latest IBD/TIPP Poll as NVAX stock continues to flounder.

Investors Business Daily

Novavax' Sees Conditional Approval Of COVID-19 Vaccine Booster In Australia As US FDA Delays Its Decision

The Australian regulatory authority has conditionally approved Novavax Inc's (NASDAQ:NVAX) Nuvaxovid (NVX-CoV2373) COVID-19 vaccine as a booster in individuals aged 18 and over. The provisional registration was based on data from Novavax's Phase 2 trial conducted in Australia, wherein a single booster dose of Nuvaxovid was administered to healthy adult participants approximately six months after…

Benzinga

5 Biotech Stocks To Watch During The Week Of June 13

Biotech stocks continued to be under pressure in the past week amid broader market weakness, precipitated by economic worries. Company-specific developments also triggered downward moves. Here's a compilation of five stocks that should be on your radar in the week of June 13: 1. Novavax

Benzinga

The hard road for the Novavax vaccine

Novavax now in financial trouble after missing peak vaccinations

Salon

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why Moderna Stock Is Moving Lower Today

Moderna Inc (NASDAQ: MRNA) shares are trading lower Thursday as vaccine stocks fall in sympathy with Novavax Inc (NASDAQ: NVAX) following reports the FDA's decision on the company's COVID-19 vacci

Investors Business Daily

Novavax Dive Continues As FDA Reviews New Covid Shot Information

Three days after the FDA's advisors recommended Novavax's Covid shot, the agency had yet to make a move, and NVAX stock toppled.

Benzinga

Why Novavax Stock Is Falling Today

Novavax Inc (NASDAQ: NVAX) shares are trading lower Thursday following reports that the U.S. Food and Drug Administration's decision on the company's COVID-19 vaccine could be delayed to review manufacturing changes.

The Independent UK

New vaccine may be option for troops with religious concerns

A COVID-19 vaccine that could soon win federal approval may offer a boost for the U.S. military: an opportunity to get shots into some of the thousands of service members who have refused the other coronavirus vaccines for religious reasons

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

HC Wainwright Says Non-mRNA COVID-19 Option Underappreciated

HC Wainwright says safety concerns were noted for Novavax Inc's (NASDAQ: NVAX) COVID-19 vaccine, but the strength of data showed that benefit outweighs risks.

Benzinga

Here's What To Watch On Novavax Stock As Latest COVID-19 Vaccine Gains Approval

Novavax, Inc (NASDAQ: NVAX) gapped up 10% to start the trading day on Wednesday, but at press time, the stock had given back almost all of its gains to trade mostly flat.

Benzinga

Why This Novavax Analyst Remains Bearish After COVID Vaccine Panel Vote

A Bank of America analyst remains bearish on Novavax, Inc (NASDAQ: NVAX) after a regulatory panel approved Novavax’s Emergency Use Authorization request fo

Investors Business Daily

Stock Market Mixed At Midday; This Leading Industry Takes Torpedo Hit

The stock market was mixed in morning trading, with the Nasdaq composite higher while the market leading shipping stocks took on water.

Benzinga

Why Novavax Stock Is Trading Higher Today

Novavax Inc (NASDAQ: NVAX) shares are trading higher Wednesday after a committee of independent U.S. Food and Drug Administration (FDA) vaccine advisors voted to recommend Novavax's COVID-19 vaccine for Emergency Use Authorization (EUA).

Benzinga

What's Next For Novavax Stock As COVID Vaccine Clears Key Hurdle In US

After last week's scare stirred by the release of the Food And Drug Administration's briefing documents, Novavax (NASDAQ: NVAX) can now heave a sigh of relief.

The Street

Stock Market Today - 6/8: Stocks Finish Lower on Mounting Stagflation Worries: Gas Nears $5 Per Gallon

Slowing growth and surging inflation may not spark a 70s-style bout of global stagflation, but dimming prospects for the U.S. economy weighed on stocks Wednesday.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.